866-997-4948(US-Canada Toll Free)

Byetta (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Jul 2013

Category :

Metabolic Disorders

No. of Pages : 48 Pages


GlobalData has released its new report, Byetta (Type 2 Diabetes) Forecast and Market Analysis to 2022. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Byetta (exenatide BID) was the first GLP-1 receptor agonist to be approved. It was developed by Amylin Pharmaceuticals and launched in 2005. It was marketed jointly by Amylin Pharmaceuticals and Eli Lilly until the two companies announced in 2011 the termination of a decade-long collaboration; now Eli Lilly will gradually transfer the responsibility for commercialization to Amylin on a market-by-market basis by the end of 2013. In 2012, Bristol-Myers Squibb and AstraZeneca jointly acquired Amylin Pharmaceuticals.

Scope

  • Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Byetta including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Byetta for the top ten countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Byetta performance
  • Obtain sales forecast for Byetta from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)
Table of Contents

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10

3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.1.4 Quality of Life 16
3.2 Symptoms 16

4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis and Referrals 18
4.1.2 Treatment Guidelines 19

5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26

6 Byetta (exenatide BID) 28
6.1 Overview 28
6.2 Efficacy 29
6.3 Non-glycemic Benefits 30
6.4 Safety 30
6.5 SWOT Analysis 31
6.6 Forecast 32

7 Appendix 33
7.1 Bibliography 33
7.2 Abbreviations 37
7.3 Methodology 39
7.4 Forecasting Methodology 39
7.4.1 Diagnosed Type 2 Patients 39
7.4.2 Percent Drug-Treated Patients 40
7.4.3 Drugs Included in Each Therapeutic Class 40
7.4.4 Launch and Patent Expiry Dates 40
7.4.5 General Pricing Assumptions 41
7.4.6 Individual Drug Assumptions 42
7.4.7 Generic Erosion 42
7.5 Physicians and Specialists Included in this Study 43
7.6 About the Authors 45
7.6.1 Analyst II - CVMD 45
7.6.2 Therapy Director - CVMD and Infectious Disease 45
7.6.3 Global Head of Healthcare 46
7.7 About GlobalData 47
7.8 Disclaimer 47

List of Table


Table 1: Symptoms of Type 2 Diabetes 17
Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes 18
Table 3: Treatment Guidelines for Type 2 Diabetes 20
Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012 23
Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012 27
Table 6: Product Profile - Byetta 29
Table 7: Byetta SWOT Analysis, 2012 31
Table 8: Global Sales Forecasts ($m) for Byetta, 2012-2022 32
Table 9: Key Patent Expiries 40
Table 10: Number of High-Prescribing Physicians Surveyed 44

List of Chart


Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *